Top

Published in:

01-06-2018 | Original Article

Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab

Authors: Satoru Nihei, Junya Sato, Toshiyuki Harada, Shoichi Kuyama, Toshiro Suzuki, Nobutsugu Waga, Yoshitaka Saito, Shigeki Kisara, Atsuko Yokota, Kouji Okada, Masami Tsuchiya, Kazufumi Terui, Yumiko Tadokoro, Takeshi Chiba, Kenzo Kudo, Satoshi Oizumi, Akira Inoue, Naoto Morikawa

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2018

Abstract

Purpose

The objective of this study was to investigate the effect of renin–angiotensin system inhibitors (RASIs) on bevacizumab (BV)-induced proteinuria in non-small cell lung cancer (NSCLC) patients.

Materials and methods

We retrospectively reviewed the medical records of NSCLC patients receiving BV between 2008 and 2014 at 11 hospitals. The patients were categorized into three groups according to their antihypertensive drug use: RASI user, non-RASI user, and non-user groups. The primary outcome was a proteinuria event of any grade during the first 6 cycles of BV treatment.

Results

A total of 211 patients were included, 89 of whom received antihypertensive drugs. Of these 89 patients, 49 were in the RASI user group, and 40 were in the non-RASI user group. The non-user group comprised 122 patients. The occurrence of proteinuria in the RASI user group was significantly lower than that in the non-RASI user group (P = 0.037) but was not significantly lower than that in the non-user group (P = 0.287). Patients using RASIs had a lower rate of proteinuria than those who did not use RASIs according to multivariate analysis (odds ratio 0.32; 95% confidence interval 0.12–0.86; P = 0.024).

Conclusion

Our study suggests that RASI administration reduces the risk of proteinuria in patients receiving BV.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550. https://doi.org/10.1056/NEJMoa061884 CrossRefPubMed

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019. https://doi.org/10.1200/JCO.2007.14.9930 CrossRefPubMed

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345 CrossRefPubMed

Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599PubMed

Lai XX, Xu RA, Yu-Ping L, Yang H (2016) Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 9:2421–2428. https://doi.org/10.2147/OTT.S96156 CrossRefPubMedPubMedCentral

Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381–1389. https://doi.org/10.1681/ASN.2010020167 CrossRefPubMedPubMedCentral

George BA, Zhou XJ, Toto R (2007) Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 49:e23–ee29. https://doi.org/10.1053/j.ajkd.2006.11.024 CrossRefPubMed

Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20:807–815. https://doi.org/10.1093/annonc/mdn713 CrossRefPubMed

Greka A, Mundel P (2012) Cell biology and pathology of podocytes. Annu Rev Physiol 74:299–323. https://doi.org/10.1146/annurev-physiol-020911-153238 CrossRefPubMed

10.

Rüster C, Wolf G (2006) Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 17:2985–2991. https://doi.org/10.1681/ASN.2006040356 CrossRefPubMed

11.

Yu SY, Qi R, Zhao H (2013) Losartan reverses glomerular podocytes injury induced by Ang II via stabilizing the expression of GLUT1. Mol Biol 40:6295–6301

12.

Shengyou Y, Li Y (2015) The effects of siRNA-silenced TRPC6 on podocyte autophagy and apoptosis induced by Ang II. J Renin Angiotensin Aldosterone Syst 16:1266–1273. https://doi.org/10.1177/1470320314543724 CrossRefPubMed

13.

US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2010 (2014) http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 31 Dec 2014

14.

Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11:733–740. https://doi.org/10.1016/S1470-2045(10)70151-0 CrossRefPubMed

15.

Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K (2016) A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 99:186–193. https://doi.org/10.1016/j.lungcan.2016.07.019 CrossRefPubMed

16.

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136. https://doi.org/10.1056/NEJMoa0707330 CrossRefPubMedPubMedCentral

17.

Eremina V, Baelde HJ, Quaggin SE (2007) Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 106:32–37. https://doi.org/10.1159/000101798 CrossRef

18.

Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46:439–448. https://doi.org/10.1016/j.ejca.2009.11.001 CrossRefPubMed

19.

Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004–3011. https://doi.org/10.1200/JCO.2012.42.3749 CrossRefPubMed

20.

Yeh J, Frieze D, Martins R, Carr L (2010) Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother 44:1010–1015. https://doi.org/10.1345/aph.1M670 CrossRefPubMed

21.

Ramirez SP, McClellan W, Port FK, Hsu SI (2002) Risk factors for proteinuria in a large, multiracial, Southeast Asian population. J Am Soc Nephrol 13:1907–1917. https://doi.org/10.1097/01.ASN.0000018406.20282.C8 CrossRefPubMed

22.

Teramachi H, Shiga H, Komada N, Tamura K, Yasuda M, Umeda M, Tachi T, Goto C, Tsuchiya T (2013) Risk factors contributing to urinary protein expression resulting from bevacizumab combination chemotherapy. Pharmazie 68:217–220PubMed

23.

Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE (1995) Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 10:1963–1974CrossRefPubMed

24.

Maki DD, Ma JZ, Louis TA, Kasiske BL (1995) Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155:1073–1080CrossRefPubMed

25.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial Group. JAMA 288:2421–2431CrossRefPubMed

26.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860. https://doi.org/10.1056/NEJMoa011303 CrossRefPubMed

27.

Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A (2004) Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65:1991–2002. https://doi.org/10.1111/j.1523-1755.2004.00620.x CrossRefPubMed

28.

Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD (2008) A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100:282–284. https://doi.org/10.1093/jnci/djm311 CrossRefPubMed

29.

Okuno Y, Kume H, Hosoda C, Homma Y (2011) Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma. Case Rep Med 2011:710216. https://doi.org/10.1155/2011/710216 CrossRefPubMedPubMedCentral

30.

Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T (2012) Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol 16:310–315. https://doi.org/10.1007/s10157-011-0543-9 CrossRefPubMed

31.

Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949–954. https://doi.org/10.1200/JCO.2009.25.4482 CrossRefPubMedPubMedCentral

32.

Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, Joensuu H (2009) Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 20:393–394. https://doi.org/10.1093/annonc/mdn729 CrossRefPubMed

33.

Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, Bosch C, Escudero P, Casado E, Jorge M, Bohn U, Pérez-Carrión R, Carmona A, Custodio AB, Maurel J (2015) Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 10:e0116527. https://doi.org/10.1371/journal.pone.0116527 CrossRefPubMedPubMedCentral

34.

Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, Molven A, Lønning PE, Akslen LA, Straume O (2012) Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One 7:e38364. https://doi.org/10.1371/journal.pone.0038364 CrossRefPubMedPubMedCentral

35.

Saif MW (2009) Managing bevacizumab-related toxicities in patients with colorectal cancer. J Support Oncol 7:245–251PubMed

36.

Cohen EP, Lemann J Jr (1991) The role of the laboratory in evaluation of kidney function. Clin Chem 37:785–796PubMed

Title: Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab
Authors: Satoru Nihei
Junya Sato
Toshiyuki Harada
Shoichi Kuyama
Toshiro Suzuki
Nobutsugu Waga
Yoshitaka Saito
Shigeki Kisara
Atsuko Yokota
Kouji Okada
Masami Tsuchiya
Kazufumi Terui
Yumiko Tadokoro
Takeshi Chiba
Kenzo Kudo
Satoshi Oizumi
Akira Inoue
Naoto Morikawa
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3580-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2018

A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells

Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner

Keynote webinar | Spotlight on antibody–drug conjugates in cancer